iifl-logo-icon 1

Ranbaxy Laboratories Ltd Merged Share Price

859.8
(5.63%)
Apr 1, 2015|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ranbaxy Laboratories Ltd Merged KEY RATIOS

Sector

Pharmaceuticals

Open

814.7

Prev. Close

814

Turnover(Lac.)

46,564.2

Day's High

869.7

Day's Low

809.45

52 Week's High

0

52 Week's Low

0

Book Value

0

Face Value

5

Mkt Cap (₹ Cr.)

36,598.55

P/E

0

EPS

0

Divi. Yield

0

Ranbaxy Laboratories Ltd Merged Corporate Action

No Record Found

Ranbaxy Laboratories Ltd (Merged) NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ranbaxy Laboratories Ltd (Merged) SHAREHOLDING SNAPSHOT

07 Mar, 2025|07:39 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 63.22%

Foreign: 63.22%

Indian: 0.00%

Non-Promoter- 21.16%

Institutions: 21.16%

Non-Institutions: 15.60%

Custodian: 0.00%

Share Price

Ranbaxy Laboratories Ltd Merged FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2014Dec-2012Dec-2011Dec-2010

Equity Capital

212.16

212.57

211.67

217.12

Preference Capital

0

0

0

0

Reserves

884.83

1,709.51

1,713.17

4,915.28

Net Worth

1,096.99

1,922.08

1,924.84

5,132.4

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2014Dec-2012

Revenue

6,864.93

6,303.54

yoy growth (%)

8.9

Raw materials

-2,872.84

-2,288.41

As % of sales

41.84

36.3

Employee costs

-1,274.72

-1,019.58

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2014Dec-2012

Profit before tax

-366.88

216.94

Depreciation

-280.17

-186.16

Tax paid

-30.57

1.94

Working capital

-1,471.1

Other operating items

View Cash Flow
Y/e 31 MarMar-2014Dec-2012

Growth matrix (%)

Revenue growth

8.9

Op profit growth

-173.25

EBIT growth

-64.94

Net profit growth

441.45

View Ratios
Particulars (Rupees in Crores.)Mar-2014Dec-2013Dec-2012Dec-2011Dec-2010

Gross Sales

13,040.32

10,604.19

12,252.88

9,970

8,550.66

Excise Duty

0

0

0

0

15.22

Net Sales

13,040.32

10,604.19

12,252.88

9,970

8,535.45

Other Operating Income

228.16

197.47

206.83

259.51

425.32

Other Income

182.83

159.13

273.17

182.19

1,097.47

Ranbaxy Laboratories Ltd Merged Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,614

122.933,87,276.661,181.050.845,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,568.7

71.31,47,802.295940.542,297513.62

Cipla Ltd

CIPLA

1,461.75

25.371,18,061.191,438.150.894,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,059

56.751,03,513.974850.922,330222.38

Dr Reddys Laboratories Ltd

DRREDDY

1,140.1

18.3395,026.5849.40.74,997.8322.46

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Ranbaxy Laboratories Ltd Merged

Management

Register Office

Registrar Office

Director

Takashi Shoda

Chairman

Tsutomu Une

Director

Rajesh V Shah

Company Secretary

S K Patawari

Managing Director & CEO

Arun Sawhney

Director

Anthony H Wild

Director

Akihiro Watanabe

Director

Kazunori Hirokawa

Director

Percy K Shroff

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Ranbaxy Laboratories Ltd, Indias largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The company has a global footprint in 46 countries, world-class manufacturing facilities in 8 countries and serves customers in over 125 countries. The company operates in two segments: pharmaceuticals and other business. Pharmaceuticals segment comprises manufacture and trading of formulations, active pharmaceuticals ingredients (API) and intermediate, generics, drug discovery and consumer health care products. Other business comprises rendering of financial services. The company has manufacturing facilities in eight countries, namely India, the United States, Brazil, Ireland, Malaysia, Nigeria, Romania and South Africa. Their major markets include the United States, India, Europe, Russia/ Commonwealth of Independent States and South Africa. The research and development activities of the company are principally carried out at their facilities in Gurgaon, near New Delhi, India.The companys shares are listed for trading on the National Stock Exchange and the Bombay Stock Exchange in India. Their Global Depository Shares (representing equity shares of the Company) are listed on the Luxembourg Stock Exchange and Foreign Currency
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.